SangCya is bioequivalent to neoral in stable cardiac allograft patients

被引：0
|
作者：
Renlund, D
Taylor, D
Kfoury, A
Campbell, B
Eidson, M
Walker, K
Irish, W
机构：
[1] SangStat Med Corp, Menlo Park, CA USA
[2] UTAH Cardiac Transplant Program, Salt Lake City, UT USA
来源：
TRANSPLANTATION | 1999年 / 67卷 / 07期
关键词：
D O I：
10.1097/00007890-199904150-00101
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
73
引用
收藏
页码：S25 / S25
页数：1
相关论文
共 50 条
  • [1] Cyclosporine metabolite pharmacokinetics and tolerability di stable hepatic allograft recipients comparing SangCya™ and Neoral® oral solutions
    Pan, SH
    Lopez, R
    [J]. TRANSPLANTATION, 1999, 67 (07) : S33 - S33
  • [2] Pharmacokinetic and clinical evaluation of SangCya and Neoral in stable, adult renal transplant patients: Preliminary results
    Gaston, RS
    Said, M
    Ward, M
    Jones, P
    [J]. TRANSPLANTATION, 1999, 67 (07) : S161 - S161
  • [3] Cyclosporin A -: SangCya® -: Gengraf® -: Neoral® -: Immunosuppressant
    不详
    [J]. DRUGS OF THE FUTURE, 2001, 26 (03) : 288 - 289
  • [4] Pharmacokinetic and safety evaluation of SangCya vs Neoral or Sandimmune in stable renal transplant recipients
    Gaston, R
    Alloway, RR
    Gaber, AO
    Rossi, SJ
    Schroeder, TJ
    Irish, WD
    Canafax, DM
    First, MR
    [J]. TRANSPLANTATION PROCEEDINGS, 1999, 31 (1-2) : 326 - 327
  • [5] Conversion of stable renal allograft recipients to a bioequivalent cyclosporine formulation
    Roza, A
    Tomlanovich, S
    Merion, R
    Pollak, R
    Wright, F
    Rajagopalan, P
    Pruett, T
    Scandling, J
    Ryan, J
    Awni, W
    Schweitzer, S
    Greco, R
    Lam, W
    Nabulsi, A
    Hoffman, R
    [J]. TRANSPLANTATION, 2002, 74 (07) : 1013 - 1017
  • [6] Conversion from Sandimmune to Neoral in patients with stable renal allograft function: UHKL experience
    Goh, BL
    Jalil, R
    Koh, SN
    Chua, CT
    Tan, SY
    [J]. TRANSPLANTATION PROCEEDINGS, 1998, 30 (07) : 3535 - 3536
  • [7] Pharmacokinetic comparison of two cyclosporine A formulations, SangCya (Sang-35) and Neoral, in stable adult liver transplant recipients
    Fisher, RA
    Pan, SH
    Rossi, SJ
    Schroeder, TJ
    Irish, WD
    Canafax, DM
    Lopez, RR
    [J]. TRANSPLANTATION PROCEEDINGS, 1999, 31 (1-2) : 394 - 395
  • [8] Development of Sang-35: a cyclosporine formulation bioequivalent to Neoral
    First, MR
    Alloway, R
    Schroeder, TJ
    [J]. CLINICAL TRANSPLANTATION, 1998, 12 (06) : 518 - 524
  • [9] Case studies: Conversion from Sandimmune to Neoral in stable renal allograft recipients
    Roth, D
    Miller, J
    [J]. TRANSPLANTATION PROCEEDINGS, 1996, 28 (04) : 2219 - 2220
  • [10] An individual bioequivalence approach to compare the intrasubject variability of two ciclosporin formulations, SangCya™, and Neoral®
    Canafax, DM
    Irish, WD
    Moran, HB
    Squiers, E
    Levy, R
    Pouletty, P
    First, MR
    Christians, U
    [J]. PHARMACOLOGY, 1999, 59 (02) : 78 - 88
12345